Among the molecular events underlying erythroid differentiation, we analyzed the signalling pathway leading to cAMP response element binding (CREB) nuclear transcription factor activation. Normal donor blood light density cells differentiated to pro-erythroblasts during the proliferative phase (10 days) of the Human Erithroblast Massive Amplification (HEMA) culture, and to orthochromatic erythroblasts, during the differentiative phase (4 additional days) of the culture. Since erythropoietin was present all over the culture, also pro-erythroblasts left in proliferative medium for 14 days continued their maturation without reaching the final steps of differentiation. p38 Mitogen Activated Protein Kinase (p38 MAPK) and CREB maximal activation occurred upon 4 days of differentiation induction, whereas a lower activation was detectable in the cells maintained in parallel in proliferative medium (14 days). Interestingly, when SB203580, a specific p38 MAPK inhibitor, was added to the culture the percentage of differentiated cells decreased along with p38 MAPK and CREB phosphorylation. All in all, our results evidence a role for p38 MAPK in activating CREB metabolic pathway in the events leading to erythroid differentiation.
protein (CREB) is a member of the CREB/ATF-l (Activating Transcription Factor 1)/CREM (CRE modulator) transcription factor family that elicits responses to a variety of signals such as growth factors and stress. CREB mediates transcriptional responses following phosphorylation at Ser133 and association with the co-activator CREB binding protein (CBP) (7) . CREB regulates a number of genes involved in different processes including proliferation, differentiation (8) , survival, memory, learning (9) and oxidative stress (10) (11) . Signalling by haematopoietic growth factors, such as GM-CSF, results in CREB activation and CREB target gene upregulation. The majority of patients with acute lymphoid and myeloid leukaemia overexpress CREB in the bone marrow. Chromosomal translocation involving the CBP and a related family member, p300, was found in specific subtypes of myeloid leukaemia, highlighting the importance of CREB and CREB-interacting proteins in the regulation of haematopoietic cell differentiation and proliferation (12) (13) . CREB is also involved in GM-CSF-activated signalling pathways in the human erythroid cell line TF-1 (14) and in haemin-induced erythroid differentiation of K562 erythrolaeukemia cell line (8) .
The conserved p38 mitogen-activated protein kinase (p38 MAPK) pathway is activated by many factors and has a variety of biological functions, depending on the cellular context (15) . These functions include regulation of inflammatory cytokine production, apoptosis, cell cycle entry, embryogenesis, placental development and cellular differentiation (16) (17) . Investigators who examined the role of p38 MAPK in erythroid cell biology have yielded conflicting results, depending on the line studied (18) (19) (20) (21) . With regard to differentiation, p38 MAPK activity is required for the haemoglobinization of SKT6 cells in response to either EPa or transient hyperosmolar or heat shock (19) of K562 cells in response to either butyrate or haemin (8, 21) and ofUT-7 cells in response to tissue inhibitor of metalloproteinase-l (TIMP-l) (22) . In primary cells different environmental conditions induce different levels ofp38 MAPK activity which have distinct functions (23) .
Thus, the aim of this study is to explore the role of CREB nuclear transcription factor and its relationship with p38 MAPK in the signal transduction pathways leading to primary human erythroblast differentiation induced by erythropoietin.
A specific p38 MAPK inhibitor, SB203580, was used to evaluate the possible involvement of this enzymatic activity in the control of CREB signalling pathway.
MATERIALS AND METHODS

Human subjects
Normal peripheral blood buffy coats from different donors were obtained for this study from the Department of Hematology -Ospedale Civile Spirito Santo, Pescara, Italy and were collected according to the guidelines established by the local committee for human subject studies.
Cell processing
Mononuclear cells were separated by centrifugation at 400 g x 30 min over Ficoll-Hypaque (GE Healthcare Life Sciences, Fairfield, CT, USA). Light density cells were collected, washed with PBS supplemented with 1% (wg/vol) bovin serum albumin and cryopreserved in 10% dimethyl-sulphoxide (Sigma, St. Louis, MO).
HEMA culture
Proliferative phase: light density cells (10 6 cells/mI) were cultured in Iscove's modified Dulbecco's medium (lMDM; PAA Laboratories GmbH, Austria) containing 20% of fetal bovine serum (FBS; Hyclone, Logan, UT) and supplemented with Stem Cell Factor (SCF, 10 ng/ml) (Peprotech, London, UK), epoietin-n (EPO, I U/ml) (Jansenn Cilag, Berchem, Belgium), interleukin-3 (lL-3, 1 ng/ml) (Peprotech), dexamethasone (10-6 M) (Sigma) and estradiol (10-6 M) (Sigma). The cultures were diluted over time with as much fresh medium as necessary to maintain cell concentration in the range of 1-2 x 10 6 cells/ml. Differentiative phase: cells were harvested at day 10 of the proliferative phase, washed with IMDM and cultured for 4 additional days in fresh IMDM in the presence of 20% FBS, EPO (1 U/mI) and human recombinant insulin (10 ng/ml) (Sigma). When indicated, cells were treated for 1 h with 20 J.lM SB203580 and then resuspended in fresh medium. In differentiating samples the p38 MAPK inhibitor was added when the cells were switched from the proliferative to the differentiative phase. Cells were stained routinely with May Grunwald-Giemsa and diaminobenzidine (DAB) dyes.
Antigenic profile
Surface erythroid markers on primary human erythroblasts were analyzed by flow cytometry using EPICS-XL cytometer and the EXP032 software (Beckman Coulter, FL, USA). Briefly, 5 x 10 5 cells suspended in PBS containing 1% FBS were incubated with CD71-FITC monoclonal antibody for 30 min on ice. An aliquot of cells was also stained with mouse IgG conjugated to FITC as an isotype control. All antibodies were from Beckman Coulter (FL, USA).
Cell cycle analysis
Approximately 0.5 x 10 6 cells per experimental condition were harvested, fixed in 70°cold ethanol and kept at 4°C overnight. Cells were then resuspended in 20 ug/ml PI and 100 ug/ml RNAse, final concentrations. Cell cycle profiles (10000 cells) were analyzed by an EPICS-XL cytometer using the EXP032 software (Beckman Coulter, FL, USA). Cells with a low fluorescence level, indicating a low DNA content, were gated as dead cells. Data were analyzed by Multicycle software (Phoenix Flow Systems, CA, USA).
Total homogenates
Cells were lysed in RIPA buffer (IX PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 ug/ml, aprotinin, 10 ug/ml. leupetin, I ug/ml, Phenyl Methane Sulfonyl Fluoride (PMSF), 1 mM DL-Dithiothreitol (DTT), 1 mM Na 3V04 ) , passed 10 times through a 25-gauge needle and centrifuged at 10000 g at 4°C. The supernatant was recovered and stored at -80°C.
Western blot analysis
Samples were collected, as indicated, at 1 h and at 4 days after SB203580 addition and/or medium change.
Total cell lysates (20 ug) were electrophoresed and transferred to nitrocellulose. After blocking in 5% non-fat milk, 10 mM Tris pH 7.5, 100 mM NaCI, 0.1% Tween-20, nitrocellulose filters were probed with mouse CREB and p-CREB (Cell Signalling Technology, Beverly, MA, USA), and developed with specific enzyme conjugated horseradish-peroxidase (Calbiochem, Darmstadt, Germany) secondary antibodies. Bands were detected by an Enhancer Chemiluminescent Labelling (ECL) detection system (Amersham Intl., U.K.).
p38 MAPKinase ELISA assay
Samples were collected, as indicated, at I h and at 4 days after SB203580 addition and/or medium change.
Activated (phosphorylated) p38 MAPKinase was quantified by Fast Activated Cell-based ELISA (FACE) kit (Active Motif, California, USA). Briefly,cells were seeded in poly-L-Lysine pre-treated wells and rapidly fixed with 8% formaldehyde. The cells were then incubated with a primary antibody recognizing either phosphorylated p38 or total p38 and subsequently with an HRP-conjugated secondary antibody. The colour, developed with a developing solution provided in the kit, was read out by a 96 well microtest plate spectrophotometer Anthos 2010 (Anthos Labtec Instruments, Salzburg, Austria). The relative number of cells per well was then determined using the provided Crystal Violet solution.
Imaging and statistics
Densitometric values of protein bands, expressed as Integrated Optical Intensity (1.0.1.), were estimated in a CHEMIDOC XRS System by the QuantiOne I-D analysis software (BIORAD, Richmond, CA, USA). Values obtained were normalized with reference to densitometric values of internal~-actin. Data were analysed using the two tailed, two sample T-test. Results were expressed as mean ± SD. Values of p<0.05 were considered significant.
RESULTS
Light density cells obtained from human peripheral blood were cultured by means of a two-step HEMA (Human Erythroblast Massive Amplification) culture method (24) : at the end of the first step (proliferative phase), lasting 10 days, most of the cells were proerythroblasts. In the following 4 days (differentiative phase), proerythroblasts continued their differentiation along erythroid lineage, until the orthocromatic stage, through polychromatic phase (Fig. lA) . The changes in cell size were evidenced also by forward scatter analysis in flow cytometry. (Fig. IB) The percentage of diaminobenzidine (DAB) positive cells, an index of haemoglobin production, was 57±4% at day 10, reaching 85±7% after 4 days of differentiative phase compared with 66±5% of the cells left for 14 days in proliferative medium. (Fig. 1C) . Moreover, as the differentiation process continued, an inhibition of proliferation was observed: in fact the percentage of the cells in GO/G 1 phase rose from 56.9±1.3% at day 10 to 64.4±1.2% after 4 additional days in differentiative medium (Table I) .
In parallel, almost all the cells at day 10 of culture expressed CD71 (94.4±3.5%). At the end of the differentiative phase only 54.6±2.8% of the cells were CD71+, while after 4 additional days in proliferative medium CD71+ was detected in 73.0±2.9% of the cells. When SB203580 was added to the culture, the percentage of CD71+ cells was always significantly higher than in controls (80.3±3.6% in proliferating cells and 75.9±4.7% in differentiating samples) (Fig. 2) . Dead cell percentage, evaluated at day 1 and day 4 of the differentiative phase and in cultures carried out in parallel in the proliferative medium, increased from 12% at day 10 to 55% at the end of the differentiative phase (day 14), compared with 31% obtained in cells in proliferative medium (day 14). Interestingly, treatment with p38 MAPK inhibitor SB203580 reduced dead cells percentage (Fig. 3) . pCREB/total CREB ratio increased at day 14 of the proliferative phase reaching the maximal value at day 14 in differentiative phase . Following SB203580 administration, no modification was observed at 1 h, while the pCREB/total CREB ratio was downreg ulated at day 14 of both proliferative and differentiative phases (Fig. 4) .
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. A) May Griinwald-Giemsa staining of erythroid cells in prolif erati ve phase (day 10) and during the progression of differentiation ofHEMA culture f rom pro-erythroblast (a) to orthochromatic (c) through polychromatic (b) erythroblast. Magnification: 40X B) Flow cytometry fo rward scatter analysis of primary human erythroblasts
Furthermore, p38 MAPK activation, indicated as ratio of phosphorylated p38 to total p38, was maximal at the end of the differentiative phase and decreased significantly in the presence ofSB203580 (Fig. 5 ). This paper is addressed to the study of morphological and molecular events related to EPOinduced in vitro erythroid differentiation. As it is not always possib le to obtain specimens with a number of cells sufficient for CD34 selection from a specific donor, and in light of the behaviour in culture of primary cells reflecting the genomic heterogeneity of the donor from whom they are obtained, we used a two-phase culture method (HEMA) that allows the mass production of primary human erythroid cells, starting from a single donor : highly homogeneous primary erythroid cells are produced in number sufficient for biochemical and molecu lar studies from very small volumes of blood .
Since previous studies performed in our laboratories disclosed an involvement of CREB nuclear transcription factor in the molecu lar events which drive haemin-induced K562 erythroleukaemia cell differentiation (8), we thought to investigate whether this nuclear transcription factor would be involved in the differenti ation of human primary erythroblasts upon erythropoietin stimulation. In fact, we found an increase in CREB phosphorylation at the end of the differentiation process of primary human erythroblasts. The finding of a reduced rate of CREB phosphorylation along with a reduced number of differentiated cells when SB203580 was added to culture, induced us to hypothe size the possibility of an upstream regulation of the CREB pathway exerted by p38 MAPK. It was interesting to note that p38 MAPK activati on was clearly increased upon terminal differentiation and significantly downregulated in the presence of SB203580 . An increase in p38 MAPK and JNK phosphorylation was found in neuronal EPO-induced recovery from anoxia and free radical induced degeneration, even though the role of this pathway is not clear (25) .
As regards the role of CREB in haematopoiesis, its involvement in megakaryocyte differentiation in both HEL cell line and primary CD34+ cells is demonstrated (26) as well as its role in normal myelopoiesis and leukaemia cell proliferation (27) . However, it is worth outlining that, while other investigations have reported a role for EPO in regulating p38 MAPK activity (19) (20) , our study is the first indicating the involvement of CREB and 
+-_
;; p38 MAPK pathway in the erythroid differentiation of primary human cells.
During erythroid cell development the transferrin receptor (recognized by CD71) level increased at the early stage of differentiation reaching a maximum per cell on proerythroblasts. Further maturation was accompanied by a decline in the number of transferrin receptors, as elsewhere already reported (28) . Erythroid late differentiation implies an alteration in the cell cycle that includes prolongation of Gland requires DNA synthesis followed by a low rate of proliferation and by the appearance of haemoglobin and erythroid structural proteins including those of the membrane skeleton . In studies on erythroid progenitors at earlier developmental stage (BFU-E), EPO induces upregulation of cyclin D3, E and A resulting in a cell cycle progression (29) but, as confirmed by our experimental data, EPOinduced effects on cell cycle differ in early compared with later stages of erythroid development, since late erythroid precursor cells exit cell cycle in response to EPO (30) . Further studies are necessary to investigate CREB /p38 MAPK , and possibly the caspase pathway connection, in influencing the balance between proliferation and terminal maturation of erythroid cells towards precursor renewal.
